Maintaining and Enhancing the Sources of Corporate Value over the Medium to Long Term
First written in FY2016. 16 of 18 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2022: 2 of 19 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust, new-field development and employees continue to be listed as sources of corporate value. - FY2022RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust, new-field development and employees continue to be listed as sources of corporate value. - FY2021RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust, new-field development and employees continue to be listed as sources of corporate value. - FY2020-Q3RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, new-field development and employees continue to be listed as sources of corporate value. - FY2020-Q2RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; and ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys.」
Stable supply, the production and supply system, the hospital network, brands and other factors continue to be listed as sources of corporate value. - FY2020-Q1RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, new-field development and employees continue to be listed as sources of corporate value. - FY2019RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust with stakeholders, new-field development and employees continue to be listed as sources of corporate value. - FY2019-Q3RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust with stakeholders, new-field development and employees continue to be listed as sources of corporate value. - FY2019-Q2RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust with stakeholders, new-field development and employees continue to be listed as sources of corporate value. - FY2019-Q1RestatedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust with stakeholders, new-field development and employees continue to be listed as sources of corporate value. As in the previous period, the record of stable supply during major earthquakes is not listed. - FY2018SoftenedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on infusions and dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on infusions and dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, hospitals, wholesalers, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; and ⑥ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust, new-field development and employees continue to be listed as sources of corporate value. The item concerning the record of stable supply during major earthquakes, which had been explicitly listed previously, has been removed from this list. - FY2018-Q3RestatedAnnual report
「In particular, we believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust with stakeholders, disaster response, new-field development and employees continue to be listed as sources of corporate value. - FY2018-Q1RestatedAnnual report
「In particular, we believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust with stakeholders, disaster response, new-field development and employees continue to be listed as sources of corporate value. - FY2017RestatedAnnual report
「In particular, we believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, trust, disaster response, new-field development and employees continue to be listed as sources of corporate value. - FY2017-Q3RestatedAnnual report
「In particular, we believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, relationships of trust, disaster response, new-field development and employees continue to be listed as sources of corporate value. - FY2017-Q2RestatedAnnual report
「In particular, we believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, relationships of trust, disaster response, new-field development and employees continue to be listed as sources of corporate value. - FY2017-Q1RestatedAnnual report
「In particular, we believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production and supply system, the hospital network, brands, relationships of trust, disaster response, new-field development and employees continue to be listed as sources of corporate value. - FY2016First statedAnnual report
「We believe that the sources of our corporate value are: ① our production and supply system, which enables the stable supply of infusions and dialysis products for artificial kidneys, among other products essential to sustaining life; ② our broad and strong network of hospitals throughout Japan, built through our pharmaceutical business, centered on dialysis products for artificial kidneys; ③ the strong brands of the “Grape Mark” and “Kindaly” in the pharmaceutical market centered on dialysis products for artificial kidneys; ④ the trust we have built with stakeholders, including patients, wholesalers, hospitals, shareholders and local communities, by managing the Company as an indispensable presence in society and giving top priority to patients’ lives and social well-being; ⑤ our vigorous pursuit of new-field development to stabilize and strengthen our management foundation, an essential and urgent task in fulfilling our social mission of ensuring a stable supply of pharmaceuticals; ⑥ our corporate efforts, through a company-wide mobilization of resources during two major earthquakes to ensure a stable supply of our core dialysis products, which enabled us to avoid situations that would have delayed dialysis treatment; and ⑦ our employees, who take pride in the Company’s management philosophy and seek the Company’s growth, development and evolution while giving top priority to patients’ lives and social well-being.」
Stable supply, the production system, the hospital network, brands, trust with stakeholders, disaster response and employees are listed as sources of corporate value.